ArticleFrontiers in cardiovascular medicine2026
Chronic quercetin supplementation modulates cardiac function and signaling pathways in aged male Wistar rat hearts subjected to ischemia-reperfusion.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Quercetin (QCT), a natural polyphenol with antioxidant, anti-inflammatory, and antithrombotic properties, has shown cardioprotective effects in various Methods: Male Wistar rats (20 months old at arrival) received QCT orally (20 mg/kg/day) for 6 weeks. After treatment, rats were euthanized and isolated hearts were perfused according to Langendorff, subjected to 30 min of global ischemia and 120 min of reperfusion. Cardiac function recovery was monitored during the first 40 min of reperfusion by assessment of electrical and mechanical parameters. Infarct size was determined by TTC staining at the end of reperfusion. In parallel groups, left ventricular tissue was collected immediately after treatment for Western blot (WB) analysis of regulatory proteins. Results: QCT administration improved electrical function, mainly by reducing QT and QTc intervals during reperfusion compared with controls. In contrast, QCT did not improve recovery of contractile function, and it did not reduce infarct size. WB analysis revealed a significantly increased Bcl-2/Bax ratio, suggesting attenuated apoptosis, while expression of other apoptotic and autophagy-related proteins remained unaffected. Conclusions: Compared with juvenile rat hearts, chronic QCT treatment exerts modest cardioprotective effects in aged hearts, characterized by improved electrical recovery and reduced pro-apoptotic signaling, independent of Reperfusion Injury Salvage Kinase (RISK) pathway or autophagy activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.